^
    1d
    Novel Therapeutic Approaches in Pediatric Acute Lymphoblastic Leukemia. (PubMed, Int J Mol Sci)
    Bispecific antibodies such as blinatumomab (anti-CD19), antibody-drug conjugates like inotuzumab ozogamicin (anti-CD22), and monoclonal antibodies such as daratumumab (anti-CD38) have demonstrated efficacy in relapsed or refractory disease with improved safety profiles. The integration of targeted and immune-based therapies into conventional regimens represents a decisive step toward precision medicine, aiming to enhance survival outcomes while reducing treatment-related toxicity and improving quality of life in ALL children. This review aims to provide a comprehensive overview of the current understanding of ALL pathobiology and therapeutic approaches, with particular emphasis on the expanding role of immunotherapeutic strategies in pediatric disease.
    Review • Journal
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin) • Darzalex (daratumumab)
    2d
    COMBAT: The Safety/Efficacy Of Daratumumab With Belatacept In Highly HLA-Sensitized Patients Awaiting Kidney Transplantation (clinicaltrials.gov)
    P2, N=5, Terminated, University Hospital, Grenoble | Phase classification: P=N/A --> P2 | N=12 --> 5 | Recruiting --> Terminated; limited clinically significant reduction on global cPRA levels (access to transplantation was unchanged), as well as restrictions in belatacept supply.
    Phase classification • Enrollment change • Trial termination
    |
    Darzalex (daratumumab)
    2d
    The real-world safety profile and potential mechanism of isatuximab: Integration of pharmacovigilance and transcriptomic analysis. (PubMed, Medicine (Baltimore))
    By synergizing real-world pharmacovigilance with transcriptomic data, this study delineates novel clinical AE signals and mechanistic insights linking CD38-driven immunometabolic dysregulation to isatuximab toxicity. These findings underscore the imperative for vigilant monitoring and tailored therapeutic strategies to mitigate risks of immune dysfunction, informing both clinical practice and future biomarker-driven interventions.
    Journal • Adverse events • Real-world evidence • IO biomarker
    |
    IFNG (Interferon, gamma)
    |
    Sarclisa (isatuximab-irfc)
    7d
    EMN39: A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant (clinicaltrials.gov)
    P3, N=1000, Recruiting, European Myeloma Network B.V. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone • Lynozyfic (linvoseltamab-gcpt)
    7d
    Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma (clinicaltrials.gov)
    P2, N=31, Active, not recruiting, City of Hope Medical Center | Trial completion date: Nov 2025 --> Jul 2026 | Trial primary completion date: Nov 2025 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    CD34 (CD34 molecule)
    |
    Darzalex (daratumumab) • melphalan
    17d
    CARO: Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex® and Dexamethasone in Multiple Myeloma Patients (clinicaltrials.gov)
    P=N/A, N=359, Completed, iOMEDICO AG | Active, not recruiting --> Completed
    Trial completion
    |
    lenalidomide • Darzalex (daratumumab) • carfilzomib • dexamethasone
    21d
    Home Based Daratumumab Administration for Patients With Multiple Myeloma (clinicaltrials.gov)
    P4, N=20, Completed, Thomas Jefferson University | Phase classification: P1 --> P4
    Phase classification
    |
    Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    22d
    A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P2, N=75, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial primary completion date: Sep 2026 --> May 2025
    Trial primary completion date
    |
    lenalidomide • Darzalex (daratumumab) • carfilzomib • dexamethasone
    23d
    Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients (clinicaltrials.gov)
    P2, N=61, Recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial primary completion date
    |
    lenalidomide • Sarclisa (isatuximab-irfc)
    23d
    Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy (clinicaltrials.gov)
    P=N/A, N=450, Recruiting, Brigham and Women's Hospital | Trial primary completion date: Jun 2025 --> Jun 2026
    Trial primary completion date
    |
    Darzalex (daratumumab)
    1m
    AQUARIUS: A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis (clinicaltrials.gov)
    P2, N=151, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: Mar 2026 --> May 2025
    Trial primary completion date
    |
    bortezomib • cyclophosphamide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • dexamethasone injection
    1m
    Favorable response to daratumumab combination therapy in patients with multiple myeloma with an immature phenotype: a report from the J-CHARGE study group. (PubMed, Int J Hematol)
    Stratifying patients with MM based on myeloma cell maturity provides meaningful information for choosing the best treatment strategy and improving patient outcomes.
    Journal
    |
    ITGA5 (Integrin Subunit Alpha 5)
    |
    lenalidomide • bortezomib • Darzalex (daratumumab)